Genetics Generation Advancement (ROCO:4160) Cyclically Adjusted Revenue per Share: NT$21.92 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4160 Genetics Generation Advancement Corp ROCO:4160
69 GF Score
Price NT$39.90
GF Value NT$53.57
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Genetics Generation Advancement Cyclically Adjusted Revenue per Share?

Genetics Generation Advancement ROCO:4160 +2.70% 69 Cyclically Adjusted Revenue per Share is NT$21.92 as of Mar. 2026. GuruFocus rates ROCO:4160 with a GF Score™ of 69/100 and a GF Value™ of NT$53.57 (Modestly Undervalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Genetics Generation Advancement's adjusted revenue per share for the three months ended in Mar. 2026 was NT$5.597. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$21.92 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Genetics Generation Advancement's average Cyclically Adjusted Revenue Growth Rate was 7.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Genetics Generation Advancement was 10.80% per year. The lowest was 9.10% per year. And the median was 10.20% per year.

As of today (2026-08-02), Genetics Generation Advancement's current stock price is NT$39.90. Genetics Generation Advancement's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$21.92. Genetics Generation Advancement's Cyclically Adjusted PS Ratio of today is 1.82.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genetics Generation Advancement was 6.60. The lowest was 1.31. And the median was 2.03.


Genetics Generation Advancement  (ROCO:4160) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genetics Generation Advancement's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=39.90/21.92
=1.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genetics Generation Advancement was 6.60. The lowest was 1.31. And the median was 2.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Genetics Generation Advancement Cyclically Adjusted Revenue per Share Related Terms


Genetics Generation Advancement Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Genetics Generation Advancement's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetics Generation Advancement Cyclically Adjusted Revenue per Share Chart

Genetics Generation Advancement Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.86 16.44 18.00 19.88 21.34

Genetics Generation Advancement Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.42 20.70 21.12 21.34 21.92

ROCO:4160 vs TMO, DHR, IDXX: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Genetics Generation Advancement's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetics Generation Advancement Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genetics Generation Advancement's Cyclically Adjusted PS Ratio falls into.


ROCO:4160
69GF Score
Genetics Generation Advancement Corp ROCO:4160
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genetics Generation Advancement Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genetics Generation Advancement's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=5.597/330.2130*330.2130
=5.597

Current CPI (Mar. 2026) = 330.2130.

Genetics Generation Advancement Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 3.096 241.018 4.242
201609 4.121 241.428 5.636
201612 3.103 241.432 4.244
201703 3.359 243.801 4.550
201706 3.266 244.955 4.403
201709 3.317 246.819 4.438
201712 3.616 246.524 4.844
201803 3.481 249.554 4.606
201806 3.562 251.989 4.668
201809 3.041 252.439 3.978
201812 3.990 251.233 5.244
201903 3.615 254.202 4.696
201906 4.298 256.143 5.541
201909 3.916 256.759 5.036
201912 4.197 256.974 5.393
202003 3.957 258.115 5.062
202006 4.030 257.797 5.162
202009 4.512 260.280 5.724
202012 4.301 260.474 5.453
202103 4.504 264.877 5.615
202106 5.266 271.696 6.400
202109 5.287 274.310 6.364
202112 4.547 278.802 5.385
202203 5.211 287.504 5.985
202206 5.655 296.311 6.302
202209 4.987 296.808 5.548
202212 4.625 296.797 5.146
202303 5.009 301.836 5.480
202306 5.503 305.109 5.956
202309 5.708 307.789 6.124
202312 5.870 306.746 6.319
202403 6.225 312.332 6.581
202406 6.342 314.175 6.666
202409 6.379 315.301 6.681
202412 5.769 315.605 6.036
202503 5.434 319.799 5.611
202506 5.368 322.561 5.495
202509 6.408 324.800 6.515
202512 6.318 324.054 6.438
202603 5.597 330.213 5.597

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$21.92 mean?
Genetics Generation Advancement (ROCO:4160) has a Cyclically Adjusted Revenue per Share of NT$21.92 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genetics Generation Advancement and its competitors.
Is Genetics Generation Advancement's Cyclically Adjusted Revenue per Share too high?
Genetics Generation Advancement's current Cyclically Adjusted Revenue per Share is NT$21.92. Overall, Genetics Generation Advancement has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's Cyclically Adjusted Revenue per Share compare to TMO and DHR?
Genetics Generation Advancement's Cyclically Adjusted Revenue per Share of NT$21.92 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genetics Generation Advancement and its competitors. Genetics Generation Advancement's current Cyclically Adjusted Revenue per Share is NT$21.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$53.57, compared to a current price of NT$39.90 — trading 25.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$21.92. Genetics Generation Advancement's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current Cyclically Adjusted Revenue per Share is NT$21.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?

Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued. The current stock price of NT$39.90 is trading 25.5% below its estimated GF Value™ of NT$53.57. GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.

Key valuation signals for ROCO:4160:

  • Cyclically Adjusted Revenue per Share: NT$21.92
  • GF Value™: NT$53.57 vs. price of NT$39.90 (25.5% below fair value)
  • GF Score™: 69/100 with 8 warning signs

No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genetics Generation Advancement Business Description

Address No. 28, Lane 36, Xinhu 1st Road, 6th Floor, Neihu District, Taipei, TWN, 11494
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
69GF Score

Get the complete analysis for ROCO:4160

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$39.90
Price
NT$53.57
GF Value